Effect of sevoflurane on the inflammatory response during cardiopulmonary bypass in cardiac surgery: the study protocol for a randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 22; no. 1; p. 25
• Main Authors: Cardoso, Thiago Augusto Azevedo Maranhão, Kunst, Gudrun, Neto, Caetano Nigro, de Ribamar Costa Júnior, José, Silva, Carlos Gustavo Santos, Bastos, Gisele Medeiros, Borges, Jéssica Bassani, Hirata, Mario Hiroyuki
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2021; BioMed Central; BMC
• Subjects: Anesthesia; Angina pectoris; Asthma; Autoimmune diseases; Body mass index; Cardiac anesthesia; Cardiac surgery; Cardiopulmonary bypass; Chronic obstructive pulmonary disease; Complications; Complications and side effects; Coronary artery bypass; Coronary vessels; Cytokines; Dosage and administration; Epigenetics; Extubation; Growth factors; Heart attacks; Heart surgery; Hospitals; Informed consent; Intervention; Kidneys; Laboratories; MicroRNAs; Patient outcomes; Patients; Postoperative period; Sevoflurane; Signal transduction; Steroids; Study Protocol; Surgery; Systemic inflammatory response; Testing; Veins & arteries; Volatile anesthetics; Brazil; Cardiopulmonary bypass; Systemic inflammatory response; Cardiac surgery; Volatile anesthetics; Cardiac anesthesia
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-020-04809-x

Recent experimental evidence shows that sevoflurane can reduce the inflammatory response during cardiac surgery with cardiopulmonary bypass. However, this observation so far has not been assessed in an adequately powered randomized controlled trial. We plan to include one hundred patients undergoing elective coronary artery bypass graft with cardiopulmonary bypass who will be randomized to receive either volatile anesthetics during cardiopulmonary bypass or total intravenous anesthesia. The primary endpoint of the study is to assess the inflammatory response during cardiopulmonary bypass by measuring PMN-elastase serum levels. Secondary endpoints include serum levels of other pro-inflammatory markers (IL-1β, IL-6, IL-8, TNFα), anti-inflammatory cytokines (TGFβ and IL-10), and microRNA expression in peripheral blood to achieve possible epigenetic mechanisms in this process. In addition clinical endpoints such as presence of major complications in the postoperative period and length of hospital and intensive care unit stay will be assessed. The trial may determine whether adding volatile anesthetic during cardiopulmonary bypass will attenuate the inflammatory response. ClinicalTrials.gov NCT02672345 . Registered on February 2016 and updated on June 2020.